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Abstract
Tumor-derived, circulating proteins are potentially useful as biomarkers for detection of cancer, for monitoring of disease
progression, regression and recurrence, and for assessment of therapeutic response. Here we interrogated how a protein’s
stability, cellular localization, and abundance affect its observability in blood by mass-spectrometry-based proteomics
techniques. We performed proteomic profiling on tumors and plasma from two different xenograft mouse models. A
statistical analysis of this data revealed protein properties indicative of the detection level in plasma. Though 20% of the
proteins identified in plasma were tumor-derived, only 5% of the proteins observed in the tumor tissue were found in
plasma. Both intracellular and extracellular tumor proteins were observed in plasma; however, after normalizing for tumor
abundance, extracellular proteins were seven times more likely to be detected. Although proteins that were more abundant
in the tumor were also more likely to be observed in plasma, the relationship was nonlinear: Doubling the spectral count
increased detection rate by only 50%. Many secreted proteins, even those with relatively low spectral count, were observed
in plasma, but few low abundance intracellular proteins were observed. Proteins predicted to be stable by dipeptide
composition were significantly more likely to be identified in plasma than less stable proteins. The number of tryptic
peptides in a protein was not significantly related to the chance of a protein being observed in plasma. Quantitative
comparison of large versus small tumors revealed that the abundance of proteins in plasma as measured by spectral count
was associated with the tumor size, but the relationship was not one-to-one; a 3-fold decrease in tumor size resulted in a 16-
fold decrease in protein abundance in plasma. This study provides quantitative support for a tumor-derived marker
prioritization strategy that favors secreted and stable proteins over all but the most abundant intracellular proteins.
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Introduction
Blood-based protein biomarkers indicative of the presence,
progression, and phenotype of a tumor are of significant clinical
interest for diagnostics and prognostics [1,2,3,4]. One common
approach to the discovery of such protein biomarkers is to
compare cancer tissues with control materials [5] and select
candidates from a list of proteins that are more abundantly
expressed in the cancer tissues; any selected candidate must be
then subsequently verified in serum or plasma. As there may be
dozens or hundreds of differentially abundant proteins identified in
such experiments [2] researchers must prioritize potential
candidates. In principle one should select those tumor proteins
that are most likely to find their way into peripheral blood at
detectable levels. Logical arguments regarding the need to give
higher priority to abundant tumor proteins, stable proteins, or
secreted or extracellular proteins are commonly made [1,6,7,8],
yet the absolute or relative values of these attributes have not been
quantified. In general, the attributes that allow cellular proteins to
find their way into the plasma in detectable levels are poorly
understood. In this study we sought to estimate the relative
importance of each of these three factors in predicting which
proteins derived from a tumor are observed in plasma and which
are not.
Ordinarily establishing what portion of a protein’s plasma
concentration originated in a tumor is challenging as plasma
abundance is affected by a combination of factors other than
tumor leakage, including endogenous host production. To
precisely measure tumor derived proteins in plasma we exploited
a mouse xenograft model where tumors are derived from human
cancer cell lines. Seventy-three percent of human tryptic peptides
are not contained in the murine tryptic peptide database. By
restricting our analysis to those peptide sequences that were
uniquely human, we were able to distinguish tumor from host
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e23090proteins. We next annotated the proteins for cellular location,
protein stability, number of tryptic peptides, and spectral count in
tissue (a measure of relative protein abundance [9], and
determined the probability of the protein being identified in
plasma. The most readily observed proteins were extracellular and
stable ones. Although our primary goal was to determine the
properties of tissue proteins that are correlated with detection in
plasma, we also compared samples from mice with large and small
tumors in order to evaluate the effect of tumor size on the
likelihood of observation of particular proteins. Tumor size was
strongly, but non-linearly, related to protein abundance in plasma.
The characteristics we evaluated here represent only a small
number of factors that relate to the chance that a protein will make
a high quality biomarker for any given disease. Factors such as
tumor shape, vascularization, nutrient penetration, histology, and
location may impact detection of tumor-derived proteins in
plasma, and relative abundance and variation of a protein in
cancer-free plasma will also impact the utilization. Although this
model may not completely reflect what can be expected in human
disease, or even in other murine models, due to differences in
tumor burden and localization, the characteristics that determine
the likelihood of detecting a tumor protein in plasma should be
transferable to human systems and will serve as a guide for
biomarker prioritization.
Results
Protein identification from tumor and plasma samples
In order to identify tumor-derived proteins detectable in blood
samples by mass-spectrometry-based proteomics, mice carrying
tumors of human cell origin were generated. A431 cells sensitive
(A431s) or resistant (A431gr derived in vivo as described in
Materials and Methods) to gefitinib were mixed with Matrigel and
subcutaneously injected into the flanks of nude athymic BALB/c
female mice. One group of animals with each tumor type (5 mice)
was treated with gefitinib and the other was not (vehicle control).
For the A431s model, the average size of tumors in untreated mice
was 2500 mm
3, three times the volume of tumors from treated
mice (750 mm
3) approximately 17 days post implant. In mice with
A431gr tumors, the tumor sizes in treated and untreated mice
were the same, around 1300 mm
3 after 18 days of implantation.
Tumor tissue and plasma were harvested on day 17 or 18 post
injection. Pooled tumor and plasma samples from treated mice
were labeled with heavy acrylamide and samples from untreated
animals were labeled with light acrylamide as previously described
[10]. Equal masses of protein from the treated and untreated mice
were mixed. As a result, four samples were generated, each was a
mixture of either tumor or plasma samples from either gefitinib
treated or untreated mice. Tumor and plasma samples were
analyzed using mass-spectrometry-based proteomics techniques.
In order to minimize false positive detection of murine peptide
sequences, we employed a stringent set of peptide and protein
filters, using only peptides having PeptideProphet [11] probability
greater than 0.95 and requiring each protein group to have at least
2 unique peptides meeting that criteria (see Materials and
Methods). A total of 2,506 human proteins were identified,
including 2,487 from the tumor analysis and 138 from plasma
(Table 1). One hundred nineteen (119) proteins were observed in
both tumor and plasma. Thus, approximately 5% of tumor
proteins were detected in plasma. A total of 445 and 395 mouse-
specific proteins were identified in the A431s and A431gr
experiments, respectively. This indicates that human-specific
tumor proteins make up approximately 20% of all proteins
identified in plasma based on our strict filtering criteria. Less than
10% of the proteins characterized in plasma were ambiguously of
the mouse or human origin; these proteins were not included in
subsequent analyses. Protein identifications were subject to
Ontology analysis. Overall, about 90% of the proteins identified
had a cellular location annotation by GO. Of the tumor proteins
observed in plasma, 40% originated from the extracellular space.
In contrast, only 10% of all proteins identified in tumor tissue were
extracellular. Thus, there was a four-fold enrichment of extracel-
lular protein identifications in plasma compared to all identified
tumor proteins. A list of these proteins is provided in Supplemen-
tary Table S1.
Tumor protein levels depend on tumor burden
All plasma samples contained mixtures of plasma of treated and
untreated mice. In the resistant tumor the treated and untreated
tumors were the same size, but the sensitive tumor was one-third
the size of the untreated. This provides an opportunity to
investigate the relationship of tumor burden on the chance that
a protein is observed. MA plots in Figure 1 shows the distribution
of log2 (treated/untreated) ratios by ion intensity, revealing that
the relative tumor protein abundance in plasma from A431s-
tumor bearing mice treated with gefitinib was 16 fold (log2(-
treated/untreated) ratios of -4) lower than those from untreated
mice (red points in Figure 1A). However, mouse proteins (black
points in Figure 1A) showed no systematic changes in treated vs.
untreated samples, thus ruling out variation in loading volume or
other specimen processing artifacts as the cause of this difference.
This as well suggests that gefitinib treatment does not grossly
change the protein expression in host. We also compared the same
log2(treated/untreated) ratios of both tumor and mouse plasma
proteins from A431gr-tumor bearing mice treated and untreated
with gefitinib, which have the same size of tumors and found no
Table 1. Summary of human tumor proteins identified and quantified in each experiment and their cellular locations.
Xenograft mouse
model
Average size
of tumors
Tissue
type
Proteins
identified
Proteins
quantified Cellular location
Extracellular Non-extracellular Not annotated
A431s Treated: 2500 mm
3
Untreated: 750 mm
3
plasma 103 18 42 54 7
tumor 2314 1153 170 1882 262
A431gr Treated=untreated
=1300 mm
3
plasma 87 18 38 42 7
tumor 2099 979 163 1705 231
doi:10.1371/journal.pone.0023090.t001
Tumor-Derived Plasma Proteins
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e23090systematic changes (Figure 1B). Thus it is reasonable to assume
that the consistent difference of tumor proteins in the plasma of
A431s-tumor bearing mice with and without treatment is
primarily resulted from differences in tumor size in treated and
untreated animals. As the ratio of tumor volume in A431s/A431gr
animals was 1:3, it is likely that factors in addition to tumor size
must convey a substantial influence on tumor protein levels in
murine plasma in order to result in a 1:16 factor in plasma. Several
potential factors could explain the non-linear relationship of the
tumor size and abundance in plasma. One could be the change of
protein constituents due to drug treatment, which cannot be ruled
out by the analyses presented above. However, when we
compared the treated and untreated A431s and A431gr tumors
of all proteins identified, we found that log2(treated/untreated)
ratios of both tumors are normally distributed around 0 (Figure 2),
which means on a proteome-wide scale there is no systematic
difference of protein abundance between treated and untreated
tumors (Figure 2). Moreover, protein level changes in plasma are
not associated with changes in tumor; that is, proteins that do not
decrease in tumor due to treatment had the same average decrease
in plasma. Another potential could be that treatment changes the
dynamics of protein secretion, or has an impact on the host ability
to remove proteins from circulation. Together this observation
suggests that the dynamics of protein production, secretion, and
degradation/elimination is not well understood and deserved
further attention.
Extracellular, stable and abundant tumor proteins are
more readily detected in plasma
Protein cellular location was annotated by Gene Ontology
database as described in Materials and Methods. While 8.7% of all
proteins were identified in solid tumors are extracellular, 44% of
the tumor proteins detected in plasma are extracellular proteins - a
five-fold enrichment. We then evaluated the association between
protein stability and the likelihood of detection. Protein stability
was estimated from the amino acid sequence using a commonly
used method (in the ExPASy proteomics tools) generated by
Guruprasad et al. [12], which is based on the correlation of protein
stability and its dipeptide composition. The stability of a protein
can be represented by a protein instability index score by
averaging the dipeptide instability weight values derived from
statistically analysis of unstable and stable proteins Guruprasad
Figure 1. MA plots of (A) A431s and (B) A431gr tumor and mouse proteins in plasma. X axis is the average intensity of MS peaks in treated
and untreated samples and Y axis represents the log2(treated/untreated) ratios. Treated samples were labeled with C13 acrylamide and untreated
samples were labeled with C12 acrylamide as described in methods. Red points are tumor proteins and black points are mouse proteins.
doi:10.1371/journal.pone.0023090.g001
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four quantiles from low to high and count the number of proteins
in each category. We found that as instability index scores
increased (low protein stability), the likelihood of detection in
plasma decreased (Table 2). However, there was no correlation
between stability and probability of detection in tumor tissue. The
difference of these two patterns was statistically significant as
evaluated by the chi-square test (p,0.001). Next, we examined
how protein abundance influenced the detection of tumor proteins
in plasma. We re-coded the spectral counts observed into quantiles
representing low, medium-low, medium-high, and high abun-
dance proteins. Percentages of proteins observed in plasma are
plotted according to their respective quantiles in spectral counts
and color coded to represent different cellular locations in Figure 3.
More than 8% of tumor proteins with spectral counts greater than
75% quantile were observed, but less than 3% of proteins
identified in plasma fall in each of the lower spectral counts
quantiles (Figure 3A and 3B). This demonstrates that highly
abundant proteins (quantile .=75%) were identified more
readily in plasma than lowest abundance proteins. Plasma proteins
with low spectral counts (quantile .25%) showed an equal ratio of
extracellular proteins to non-extracellular proteins. However,
proteins with high spectral counts (quantile .=75%) were
enriched for non-extracellular proteins. This suggests that the
probability that a non-extracellular protein will be present in
plasma is more dependent on the protein abundance than that of
extracellular proteins.
Prediction of protein cellular location, stability, and
abundance association with the probability of
observation of tumor proteins in plasma
We used a logistic regression model to estimate how the cellular
location, stability, and abundance associate with the presence of
Figure 2. Histograms of (A) A431s and (B) A431gr tumor protein treated/untreated ratios. Ratios are in log2 scale.
doi:10.1371/journal.pone.0023090.g002
Table 2. Numbers of human tumor proteins observed or not observed in plasma by instability index.
Observed in plasma Not observed in plasma Chi-square test
instability index ,=25% 25-50% 50-75% .75% ,=25% 25-50% 50-75% .75%
A431s 37 20 12 11 542 558 566 568 7.3e-05
A431gr 32 22 12 11 493 503 512 514 0.001
doi:10.1371/journal.pone.0023090.t002
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each parameter on probability of protein detection. The
coefficients and significance (p values) are listed in Table 3; the p
values and magnitudes from individual analyses and the joint
analysis for all of the respective features are shown. For a low
probability event, the increase in probability is close to the
exponential value of the regression coefficients. Our data indicate
that cellular location had the largest single impact on the
probability that a protein will be detected in the plasma:
Extracellular proteins were 7 (e
1.95,7) times more likely to be
observed in plasma than non-extracellular proteins, assuming all
other factors are the same. Protein stability and abundance also
influenced the likelihood of protein detection. Stable proteins
(those with instability scores of less than 40, see Materials and
Methods) were about twice as likely to be detected in plasma as less
stable proteins (e
0.87,2.4 times for A431s data and e
0.51,1.7
times for A431gr data). In addition, the probability of detection of
a tumor protein was higher by 50% (e
0.44,1.55) if its spectral
count was doubled, all else similar. The number of tryptic peptides
was not significantly associated with the likelihood of detection;
this was surprising given that proteins that have more tryptic
peptides have more chance of being sampled by MS/MS. Neither
coefficients nor p values changed significantly when the logistic
regression was performed in the marginal mode rather the
multivariate mode.
To validate the use of a logistic regression model in predicting
factors that affect tumor proteins to be detected in plasma, receiver
operating characteristic (ROC) curve was used. ROC curves were
plotted for our classification model, using one data set (A431s/
A431gr) as training set to predict which proteins would be
observed in plasma for the other (A431gr/A431s) [13], area under
curves (AUCs) (Figure 4) of both curves were close to 0.8,
suggesting that these tests were valid. Selection of 10% of all tumor
proteins using the model would capture 60% of all plasma
proteins.
Discussion
Plasma, rather than tissues or other bodily fluids, is the most
common source for biomarker discovery [14]. However, only a
small fraction of proteins detected in blood are cancer related
because most cancer-specific proteins from the tumor tissue are
diluted as they leak into the interstitial or proximal fluid and
lymph, and are diluted further when they enter the blood [15].
During the course of biomarker exploration using high-through-
put, large scale studies such as mass-spectrometry based proteomic
techniques, knowledge of which tumor-specific proteins are likely
to be observed in plasma will be important for data interpretation
and pathway analyses. One approach to identifying plasma
biomarkers is to identify proteins that are over-abundant or
unique to cancer tissues. Because development of blood-based
assays can be time-consuming and costly, often only a subset is
then selected for further validation.
We analyzed LC-MS/MS data of tumor tissue and plasma from
mice xenografted with human A431 cells that were either sensitive
or resistant to gefitinib. Because of sequence heterogeneity, this
model allowed us to readily distinguish tumor proteins, which were
of human origin, from the host mouse proteins. We found that
Table 3. Association of cellular location, protein stability,
abundance, and number of tryptic peptides of human tumor
proteins with presence in plasma using logistic regression.
multivariate marginal
Coefficient P value Coefficient P value
A431s Extracellular 1.95 7.1e-13 1.91 1.2e-13
Stability 0.87 0.001 1.06 9.8e-06
Spectral counts 0.44 9.4e-13 0.43 3.8e-15
# of tryptic
peptides
-0.008 0.05 -0.0008 0.82
A431gr Extracellular 2.01 9.9e-12 2.00 8.2e-13
Stability 0.51 0.076 0.81 0.002
Spectral counts 0.45 3.8e-12 0.41 3.9e-13
# of tryptic
peptides
-0.007 0.098 0.001 0.74
doi:10.1371/journal.pone.0023090.t003
Figure 3. Percentage of (A) A431s and (B) A431gr tumor
proteins observed in plasma shown by spectral count in
quantile scale and different cellular locations. X axis is spectral
counts plotted in quartile scales and increase from left to right. Y axis is
the percentage of all tumor proteins identified in plasma. Black bars:
non-extracellular; grey bars: extracellular proteins; empty bars: not
annotated. Spectral counts were plotted in quartile scale and increase
from left to right.
doi:10.1371/journal.pone.0023090.g003
Tumor-Derived Plasma Proteins
PLoS ONE | www.plosone.org 5 July 2011 | Volume 6 | Issue 7 | e2309020% of the mouse plasma proteins identified are from the tumor,
higher than the mass of the tumor to the whole mouse which
ranges from 4–10%. However, based on spectral count, the total
spectral count of tumor proteins is only 4.5% of all plasma
proteins. And it should be noted that certain abundant mouse
proteins have been removed prior to the mass spectrometry
analysis. The high presence of protein IDs from tumor may result
from the abnormal active states of cancer cells. Our analysis
revealed that the probability of detection of a tumor protein in
plasma was associated with the extracellular location of the
protein, higher stability and abundance, and the larger tumor size.
Of these factors, cellular location contributed most, i.e. extracel-
lular proteins, even those of low abundance, were often observed
in plasma. In contrast, only highly abundant nuclear proteins were
observed in plasma. Our findings suggest that researchers should
have a strong preference for proteins that are secreted, stable, and
avoid proteins that are intracellular unless they are highly
abundant. As shown in Figure 4, we used the weights on each of
these factors to compute a linear classifier score capable of
capturing 60% of the detectable tumor proteins while selecting
only 10% of other proteins identified in tissues. The exact weights
may differ based on tumor occurring site and other factors, but the
relative magnitude of these factors may provide a means for
researchers to select a small set of markers from among all possible
candidates. The instability index scores of proteins identified
formed a normal distribution with a mean value of approximately
40 (Supplementary Figure S1), the cutoff chosen to distinguish the
stable and unstable proteins. The distribution of tumor proteins in
plasma was left shifted (green), compared to those not detected in
plasma (black). This is consistent to the result shown above
(Table 2). When we standardized the score and implemented
logistic regression, the coefficient became 0.48 with a p value of
0.001. This suggests that proteins with scores below 1 standard
deviation from the mean (about 16% of the total proteins) were
62% more likely to be detected in the plasma than were less stable
proteins.
Tumor protein abundance in plasma was lower in samples from
mice with smaller tumors than in those with larger tumors
(gefitinib-treated vs. untreated mice with sensitive tumors);
however, the ratio of tumor volumes in treated vs. untreated mice
was smaller than the ratio of protein abundances. We suspect that
this discrepancy is due to the sensitivity of the mass spectrometer.
Or it may be that proteins derived from larger tumors with higher
stability may be non-linearly enriched or that necrosis within the
tissue is volume related. An experiment with plasma and tissues
collected from animals with a range of tumor sizes would allow
testing of these hypotheses. In this analysis, tumor size difference
was result from drug treatment, which may raise the concern of
altering protein expression. Our analysis found that although that
a small number of protein abundances did vary, drug treatment
did not grossly alter protein expression levels of both tumor (see
Results and Figure 2) and its host. An alternative way to acquire
different sizes of tumor without drug treatment is to collect tumors
at different time, which has other uncertain factors such as
different mouse ages, too. Proteins varied from the drug treatment
warrant further investigation but are not within the scope of this
study.
There are many other potential considerations for prioritizing
cancer biomarkers, such as proteins that are abundant and
endogenous in ordinary human plasma will not be good
Figure 4. Receiver operating Characteristic (ROC) curves showing the prediction of tumor proteins detected in plasma by using
A431s data to predict proteins in A431gr xenograft model (red) or using A431gr data to predict proteins in A431s xenograft model
(blue).
doi:10.1371/journal.pone.0023090.g004
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tumor proteins are most likely to be detected in plasma. Obviously,
not all tumor proteins detected in plasma can be satisfying
candidates since some of them may have endogenous counter-
parts. In our list of tumor proteins detected in plasma, 64 out of
138 have endogenous mouse homologues and for some proteins,
the mouse homologues are highly abundant. These abundant
proteins will not be good markers; the low abundant ones require
further analysis and validation of significance of changes in the
human plasma under disease condition. In summary, it is
important to interrogate as many necessary factors for the
selection of a good candidate. Our study suggests that stable
proteins excreted by tumor cells should be given highest priority in
further studies.
Materials and Methods
In vivo xenografts and tumor and plasma samples
Matrigel (BD Biosciences, Sparks, MD) was mixed 1:1 with
2610
9 A431 cells (ATCC, Manassas, VA) and subcutaneously
injected into the flanks of nude athymic BALB/c female mice
obtained from Charles River Breeding Laboratories (Wilmington,
MA). The A431 gefitinib-resistant tumor cells were selected by
serial passage of A431 subcutaneous xenografts in presence of
50 mg/kg of gefitinib (AstraZeneca, London, UK) for nine
months. Animals were maintained in pressurized ventilated cages
at the Cedars-Sinai Medical Center Vivarium. All animal
experiments were performed as per the institutional guidelines
and were approved by the Institutional Animal Care and Use
Committee at Cedars-Sinai Medical Center (CSMC) (IACUC
Number 001276). Gefitinib was administered orally daily to
twenty animals at around 10–12 weeks old. Control animals
received vehicle alone (20 animals). The tumor volumes were
measured twice a week with a digital vernier caliper and were
calculated as: p/6 x (larger diameter)6(smaller diameter). Tumor
tissue and plasma were harvested after 17 or 18 days post injection
At this time, for the A431s model, the average size of tumors in
untreated mice was 2500 mm
3, three times the volume of tumors
from treated mice (750 mm
3). In mice with A431gr tumors, the
tumor sizes in treated and untreated mice were the same, around
1300 mm
3. The mass ratio of tumor to whole mouse ranges from
4–12%. Frozen tumor pieces from 5 mice were individually
ground in liquid nitrogen with the aid of a ceramic mortar and
equal masses of individual tumor homogenate were pooled and
suspended in RAF buffer. The homogenate was centrifuged for
5 min at 2006 g. The supernatant was sonicated on ice for 2
minutes and centrifuged for 1 hr at 12,0006g. The supernatant
(soluble fraction) was cleared through a 0.22-mm filter. Sera from 5
mice were pooled and depleted using two MARS-3 columns
(Agilent, Santa Clara, CA) connected in tandem with HPLC. The
unbound fraction was concentrated to a final concentration of
2 mg/ml. Tumor and plasma samples from animals untreated vs.
treated with gefitnib were labeled with C12 vs. C13 acrylamide
respectively as described in Faca et al. [10].
Fractionation of A431 tumor and mouse plasma samples
Tumor samples were fractionated by reversed-phase chroma-
tography using 1 mg of total protein. All samples were reduced
with DTT (0.6 mg DTT/mg protein) and alkylated with
iodoacetamide (3 mg IA/mg protein) prior to chromatography
as described elsewhere [16]. Separation was performed in a
POROS R1/10 column (4.6650 mm, Applied Biosystems, Foster
City, CA) at a flow rate of 2.7 ml/min using a linear gradient of 10
to 80% of organic solvent over 30 minutes. The aqueous solvent
was 5% acetonitrile/95% water/0.1% trifluoracetic acid; the
organic solvent was 75% acetonitrile/15% isopropanol/10%
water/0.095% trifluoracetic acid. Fractions were collected at a
rate of 3 fractions/minute and 72 fractions were collected. Each
fraction was individually digested in solution with trypsin (400 ng/
fraction) [17]. Adjacent fractions were combined based on protein
chromatography features, resulting in a total of 25 fractions for
mass spectrometry analysis. Plasma samples were subjected to two-
dimensional fractionation based on previously described Intact-
protein Analysis System (IPAS) approach [17,18,19,20]. Basically,
the sample was diluted to 10 ml with 20 mM Tris (pH 8.5) in 6%
isopropanol, 4 M urea and immediately injected on an anion
exchange, Mono-Q 10/100 column (Amersham Biosciences,
Piscataway, NJ, USA) for the first dimension of the protein
fractionation. The buffer system consisted of solvent A (20 mM
Tris, pH 8.5, in 6% isopropanol, 4 M urea pH 8.5) and solvent B
(20 mM Tris in 6% isopropanol, 4 M urea, 1 M NaCl). The
separation was performed at a flow rate of 4.0 ml/min in a
gradient of 0–35% solvent B in 44 minutes; 35–50% solvent B in 3
minutes; 50–100% solvent B in 5 minutes; and 100% solvent B for
an additional 5 minutes. A total of 12 pools were collected. Each
pool was then subjected to a second dimension of separation by
reversed-phase chromatography. The reversed-phase fractionation
was carried out on a Poros R2 column (4.6650 mm; Applied
Biosystems) using trifluoroacetic acid/acetonitrile as a buffer
system (solvent A, 95% H2O, 5% acetonitrile, 0.1% trifluoroacetic
acid; solvent B, 90% acetonitrile, 10% H2O, 0.1% trifluoroacetic
acid) at a flow rate of 2.7 ml/min. The gradient was 5% solvent A
until the absorbance reached baseline (desalting step) and then 5–
50% solvent B in 18 minutes; 50–80% solvent B in 7 minutes; and
80–95% solvent B in 2 minutes. During the run, 72 900-ml
fractions were collected. Each fraction was individually digested in
solution with trypsin (400 ng/fraction) and the fractions were
grouped into 8 pools based on chromatographic features,
corresponding to a total of 96 fractions for analysis from each
experiment.
Protein identification and quantification by LC-MS/MS
Protein identification by LC-MS/MS was performed as
described previously [17]. Briefly, pools of fractions were
individually analyzed by LC-MS/MS in a LTQ-FTICR or
LTQ-ORBITRAP mass spectrometer (Thermo-Finnigan, Wal-
tham, MA) coupled to a nanoflow chromatography system
(Eksigent, Dublin, CA) using a 25-cm column (Picofrit 75 mm
ID, New Objectives, Woburn, MA) packed in-house with
MagicC18 resin (Michrome Bioresources, Auburn, CA) over a
90-minute linear gradient. Acquired data was automatically
processed using default parameters, except where noted, using
the Computational Proteomics Analysis System (CPAS), V8.2
[21]. The tandem mass spectra were searched against version 3.44
of the human IPI (71,884 protein entries) and mouse (version 3.44
with 55,078 protein entries) databases. The searches were
performed with X!Tandem (2008.02.01). The mass tolerance for
precursor ions was set to 1.5 Daltons. The mass tolerance for
fragment ions was set to 0.5 Daltons. A fixed modification of
71.0371 mass units was added to cysteine residues for database
searching to account for the acrylamide modification and 3.01
Daltons were used as variable modification to account for the
heavy cysteine isotope. All identifications with a PeptideProphet
[11] probability greater than 0.95 were submitted to ProteinPro-
phet [22] and each of the subsequent protein identifications were
required to have at least two unique peptides with tryptic
fragments (1 missed cleavage) with allowance for variable
modifications on E = 218.011, K=6.020, M=15.995, and
Tumor-Derived Plasma Proteins
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e23090Q=217.027. In order to assign a species, we required at least
one unique human peptide for identification as a human protein,
referred to throughout this manuscript as ‘‘tumor proteins’’. One
unique mouse peptide was required for identification as a ‘‘mouse
protein’’. The Q3 algorithm [10], developed to accommodate a
three-Dalton mass shift in heavy and light peptides, was used to
compute the ratios between the light and heavy isotopic pairs (i.e.,
the untreated vs. treated changes). A spectral count method [9]
was used to estimate the relative abundance of proteins. More
specifically, peptide spectra with PeptideProphet [11]probability of
greater than 0.95 or an error rate of 1% were counted for each IPI
entry identified.
Comparison of human and mouse database entries
Protein sequences in human database (human IPI v.3.44) and
mouse database (mouse IPI v. 3.44) were computationally digested
with trypsin and a minimum of seven residues was used to match
the X! Tandem default search parameter of the minimum parent
fragment. A total of 673,735 human peptides were found and
490,809 (73%) peptides were uniquely in the human database;
182,926 (27%) peptides were also observed in the mouse database.
Data processing and integration
To facilitate comparisons of protein groups among samples,
data were aligned by tracking all proteins that were members of a
single ProteinProphet group as described by Fang et al. [23]. This
provided an analytic data set with one row for each protein group
and specifically a column with values indicating the spectral count
for proteins in each sample consistent with that group. The cellular
location for each protein sequence was determined using the
March 2008 generic GO slim from the GO consortium (http://
www.geneontology.org/GO.slims.shtml). GO slim files are re-
duced ontologies with significantly fewer categories than the
complete GO ontology. For example, there were about 2400
distinct cellular component categories in the full ontology as of
March 2008. The generic March 2008 GO slim file has only 37
categories, several of which are not present in mammalian cells.
The script ‘‘map2slim’’ (available from GO) was used to assign
proteins to their nearest GO category and to identify those that are
located in the extracellular or plasma membrane. Based on GO
definition, the term ‘‘extracellular’’ in this study refers to space
outside the plasma membrane and is intended to annotate gene
products that are not tightly attached to the cell surface.
Therefore, proteins annotated with ‘‘extracellular’’ are basically
proteins ‘‘secreted’’ into the medium. In cases that an IPI had
multiple locations, the protein was considered extracellular as long
as one annotation was ‘‘extracellular space’’.
Protein stability was estimated by calculating the Instability
Index (II) based on its primary sequence [12]. The instability index
for a given protein was calculated by the summation of the
dipeptide instability weight values (DIWV) and then normalized to
the length of the sequence. As recommended by Guruprasad et al.
[12] , proteins with values less than 40 were defined as stable,
whereas those with values greater than 40 were annotated as
unstable.
Statistical analysis
We used logistic regression to estimate or predict the probability
that a protein observed in tissue will be observed in plasma. The
equation relates the log odds ratio to one or more predictors.
Specifically, variations estimated were spectral count (reflective of
protein abundance), cellular location (whether it is extracellular),
protein stability, and number of theoretical tryptic peptides
(reflective of the protein length). We also tested an interaction
term among cellular location, the stability score and spectral
count, but those terms were not statistically significant and so were
removed. The final equation is given by:
Log(p=(1-p))~b0 z b1  Log(spectral count z 1)
z b2  Extracellular z
b3  Stability z
b4  Number of Tryptic-Peptides
The value b0 represents the baseline probability and is generally
not of interest given the relatively large tumor burden in the mouse
model used here compared to humans. Other coefficients
represent the increase (decrease) in log-odds of being detected
based on the value; for practical purposes one can interpret
exponential of these values as the increase in probability for the
low probability events.
Supporting Information
Figure S1 Density plots of protein instability index scores of tumor
proteins detected ornot in plasma.X axis is the protein instability index
scores and y axis is density. The green line is the distribution of tumor
proteins observed in plasma and black one is tumor proteins not
detected in plasma. Proteins with instability score of ,40 are stable
proteins as suggested by Guruprasad et al. [12].
(TIF)
Table S1 Proteins identified in the tumor and plasma of the
A431 human cell lines xenografted mouse model.
(XLS)
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